Consistent with these studies, we found that both gefitinib-resistant NSCLC cells and gefitinib-resistant mouse lung tumor tissues acquired EMT phenotype along with IGF1R activation. The gene discussed is IGF1R; the disease is non-small cell lung carcinoma.